
Metropolis Healthcare Share Price: 11.8% CAGR in 3 Years as the Mumbai-Based Pathology Chain Compares With Dr Lal PathLabs, Fortis Healthcare and Narayana Health
Updated: 19 Nov 2026 • 3:09 pm
Posted by:

Metropolis Healthcare Share Price: 11.8% CAGR in 3 Years as the Mumbai-Based Pathology Chain Compares With Dr Lal PathLabs, Fortis Healthcare and Narayana Health
Metropolis Healthcare previous close Rs 564.30. 3-year CAGR 11.8%. Up 1.4x since 17 Nov 2023. ROE 13.66%. Market cap Rs 11,704 crore.
Quick Answer
The Metropolis Healthcare share price closed at Rs 564.30 on 18 November 2026, a compounded annual return of 11.8% over three years. That compares with Dr Lal PathLabs at 13.4%, Fortis Healthcare at 30.6% and Narayana Health at 15.5%. The company has a market cap of Rs 11,704 crore and a P/E of 51.93 against an industry P/E of 63.96.
The Metropolis Healthcare share price closed at Rs 564.30 on 18 November 2026 and has compounded at 11.8% a year over three years. Metropolis Healthcare, based in Mumbai, runs a network of pathology labs, collection centres and home collection services in India and abroad.
This article places that return beside Dr Lal PathLabs, Fortis Healthcare and Narayana Health. We calculate the three-year CAGR for all four and set the results next to market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.
Click Here – Get Free Investment Predictions
How Much Has the Metropolis Healthcare Share Price Returned in 3 Years?
The Metropolis Healthcare stock closed at Rs 404.35 on 17 November 2023 and at Rs 564.30 on 18 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.40 lakh, which is a CAGR of 11.8%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Metropolis Healthcare can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
A diagnostics business grows when more patients are tested and when each patient takes more tests. The Metropolis Healthcare share price follows that volume and mix story, with a modest price return alongside a light balance sheet.
Metropolis Healthcare vs Dr Lal PathLabs, Fortis Healthcare and Narayana Health: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 17 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 18 November 2026.
| Company | Close on 17 Nov 2023 | Previous close (18 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Fortis Healthcare | Rs 356.30 | Rs 793.55 | 2.2x | 30.6% |
| Narayana Health | Rs 1,225.90 | Rs 1,891.30 | 1.5x | 15.5% |
| Dr Lal PathLabs | Rs 1,349.38 | Rs 1,965.40 | 1.5x | 13.4% |
| Metropolis Healthcare | Rs 404.35 | Rs 564.30 | 1.4x | 11.8% |
The Metropolis Healthcare stock ranks fourth of the four at 11.8%. The companies ahead are Fortis Healthcare (30.6%), Narayana Health (15.5%) and Dr Lal PathLabs (13.4%). By market cap the company ranks fourth of the four at Rs 11,704 crore. Fortis Healthcare is the largest of the four by market cap, and Metropolis is the smallest, so the comparison shows how a focused lab chain sits beside larger healthcare names.
Look at the Metropolis Healthcare share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Fortis Healthcare | Rs 60,170 crore | 56.65 | 63.96 | 9.91% | 0.30 |
| Narayana Health | Rs 38,635 crore | 44.97 | 63.96 | 17.17% | 1.21 |
| Dr Lal PathLabs | Rs 32,976 crore | 56.08 | 63.96 | 21.32% | 0.09 |
| Metropolis Healthcare | Rs 11,704 crore | 51.93 | 63.96 | 13.66% | 0.16 |
By market cap, Fortis Healthcare is the largest of the group at Rs 60,170 crore, while the Metropolis Healthcare stock stands at Rs 11,704 crore, about 19% of that size. On earnings, Metropolis Healthcare shares trade at a P/E of 51.93 against an industry P/E of 63.96, a discount of about 19% to the sector, which leaves room if earnings keep growing. Peer multiples are Dr Lal PathLabs at 56.08, Fortis Healthcare at 56.65 and Narayana Health at 44.97.
Return on equity is 13.66% for the Metropolis Healthcare stock, which ranks third among the four, and debt to equity stands at 0.16. Trailing EPS is Rs 10.86. Metropolis trades at a P/E of 51.93 against an industry P/E of 63.96, with a price to book of 7.13. That makes it the second lowest P/E in the group.
What Is Driving the Metropolis Healthcare Stock?
Metropolis earns revenue from routine tests, specialised tests and wellness packages sold through labs, collection centres and partner hospitals. Specialised tests carry higher realisation than routine ones.
The company earns an ROE of 13.66% and carries a debt to equity of just 0.16, which is the third highest in the group. Its P/E of 51.93 sits below the industry P/E of 63.96.
Investors who follow the Metropolis Healthcare share price usually track test volumes, revenue per patient, the share of specialised tests and operating margin.
How the Established Players Stack Up
Dr Lal PathLabs is a Delhi-based diagnostics company with a large network of labs and collection centres. It compounded at 13.4% a year, on a market cap of Rs 32,976 crore and an ROE of 21.32%.
Fortis Healthcare is a Gurugram-based hospital chain with a diagnostics arm and hospitals in many cities. It compounded at 30.6% a year, on a market cap of Rs 60,170 crore and an ROE of 9.91%.
Narayana Health is a Bengaluru-based hospital chain known for its cardiac care. It compounded at 15.5% a year, on a market cap of Rs 38,635 crore and an ROE of 17.17%.
What Should Investors Track Next?
Three things are worth watching on the Metropolis Healthcare share price. First, test volume growth in the next quarterly result. Second, the share of specialised tests in revenue. Third, operating margin as the network expands.
At a P/E of 51.93 the stock trades below the industry P/E of 63.96, which leaves room if volumes keep growing. Lab pricing is competitive, so follow each result closely.
Check the Univest Screener for live fundamentals of diagnostics stocks
How to Compare Diagnostics Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Metropolis Healthcare stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Metropolis Healthcare share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Metropolis Healthcare share price and compare diagnostics stocks live.
A Focused Lab Chain Beside Larger Healthcare Names
The Metropolis Healthcare share price compounded at 11.8% a year over three years, against 30.6% for Fortis, 15.5% for Narayana Health and 13.4% for Dr Lal PathLabs. Its market cap is Rs 11,704 crore.
Fortis Healthcare brings the fastest return, Dr Lal PathLabs brings the highest ROE and Narayana Health brings the lowest P/E. Metropolis offers a pure diagnostics model with low debt.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Metropolis Healthcare share price today?
Ans. Metropolis Healthcare closed at Rs 564.30 on 18 November 2026, according to NSE data. It has a market cap of Rs 11,704 crore and a P/E of 51.93. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Metropolis Healthcare stock?
Ans. Metropolis Healthcare delivered a price CAGR of 11.8% over three years, moving from Rs 404.35 on 17 November 2023 to Rs 564.30 on 18 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Metropolis Healthcare better than Dr Lal PathLabs?
Ans. Dr Lal PathLabs delivered the higher three-year CAGR at 13.4% against 11.8% for Metropolis Healthcare. Dr Lal PathLabs has the larger market cap at Rs 32,976 crore against Rs 11,704 crore for Metropolis Healthcare. Dr Lal PathLabs earns the higher ROE at 21.32% against 13.66%. Metropolis Healthcare trades at the lower P/E of 51.93 against 56.08. The better choice depends on whether you weigh recent return, size, profitability or valuation most.
What does Metropolis Healthcare do?
Ans. Metropolis Healthcare Limited is a Mumbai-based diagnostics company that operates pathology laboratories, collection centres and home sample collection services.
Is the Metropolis Healthcare stock debt free?
Ans. The debt to equity ratio of the Metropolis Healthcare stock is 0.16 and its return on equity is 13.66%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Metropolis Healthcare expensive compared with the industry?
Ans. Metropolis Healthcare trades at a P/E of 51.93 against an industry P/E of 63.96. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which diagnostics stock gave the highest return in 3 years?
Ans. Among the companies compared here, Fortis Healthcare delivered the highest three-year CAGR at 30.6%, followed by Narayana Health at 15.5%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.
Recent Articles

3 Dairy Products Company, Luxury Hotels Operator and Suiting Fabrics Maker Stocks With a Strong Future Roadmap: Heritage Foods, Indian Hotels Company and Siyaram Silk Mills
19 November 2026

3 Container Rail Logistics Company, Business Hotels Owner and Home Electricals Maker Stocks With a Strong Future Roadmap: Gateway Distriparks, SAMHI Hotels and V-Guard Industries
19 November 2026

3 Copper Ore Producer, Infrastructure Builder and Gold Jewellery Seller Stocks With a Strong Future Roadmap: Hindustan Copper, Larsen & Toubro and PN Gadgil Jewellers
19 November 2026

3 Agrochemicals Company, Cement Producer and CNC Machining Centres Maker Stocks With a Strong Future Roadmap: Insecticides India, JK Cement and Jyoti CNC Automation
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
3 Dairy Products Company, Luxury Hotels Operator and Suiting Fabrics Maker Stocks With a Strong Future Roadmap: Heritage Foods, Indian Hotels Company and Siyaram Silk Mills
3 Container Rail Logistics Company, Business Hotels Owner and Home Electricals Maker Stocks With a Strong Future Roadmap: Gateway Distriparks, SAMHI Hotels and V-Guard Industries
3 Copper Ore Producer, Infrastructure Builder and Gold Jewellery Seller Stocks With a Strong Future Roadmap: Hindustan Copper, Larsen & Toubro and PN Gadgil Jewellers
3 Agrochemicals Company, Cement Producer and CNC Machining Centres Maker Stocks With a Strong Future Roadmap: Insecticides India, JK Cement and Jyoti CNC Automation
3 Tractors Maker, Textile Specialty Chemicals Maker and Defence Optics Maker Stocks With a Strong Future Roadmap: Escorts Kubota, Rossari Biotech and Paras Defence and Space Technologies

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





